Summary
- Current Price
- As of today, RNA price is $13.70, down -2.07% on
- Current Price All-Time High
- RNA price is currently -18.31% below its historical high of $16.77 set on
- Market Cap
- RNA current market cap is $2B, with unknown 1-year change
- PE Ratio
- RNA PE ratio is unknown
- Revenue
- RNA current annual revenue is $18.76M, up +72.11% year-over-year
- Next Earnings
- The next earnings release for RNA is on
Profile
| Metric | Value |
|---|---|
| Full Name | Atrium Therapeutics, Inc. |
| Ticker | NASDAQ: RNA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | atriumtherapeutics.com |
| Employees | - |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $13.70 | |
| Price, 1D Change | -2.07% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.33 | |
| Revenue | $19M | |
| Revenue, 1Y Change | +72.11% | |
| EPS | -$4.97 | |
| EPS, 1Y Change | -72.11% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$4.97 | |
| EPS Estimate | N/A | -$4.14 |
| EPS Est. Change | N/A | +16.73% |
| Revenue | $18.76M | |
| Revenue Estimate | N/A | $8.00M |
| Revenue Est. Change | N/A | -57.34% |
| Current Price | $13.70 | |
| Price Target | - | $25.00 |
| Price Tgt. Change | - | +82.48% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.86 | -$2.89 | -1.09% | |
| -$4.49 | -$4.97 | -10.62% | |
| -$4.14 | N/A | +16.73% | |
| -$4.62 | N/A | +7.07% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $9.75M | $10.90M | +11.76% | |
| $18.36M | $18.76M | +2.16% | |
| $8.00M | N/A | -57.34% | |
| $8.00M | N/A | -57.34% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | - | |
| Price, 3Y | - | |
| Market Cap, 1Y | - | |
| Market Cap, 3Y | - | |
| Revenue, 1Y | +72.11% | |
| Revenue, 3Y | +103.33% | |
| EPS, 1Y | -72.11% | |
| EPS, 3Y | -49.04% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $13.70 | |
| SMA 200 | $13.98 | |
| SMA 200 vs Price | +2.04% | |
| SMA 50 | $13.98 | |
| SMA 50 vs Price | +2.04% | |
| Beta | 0.33 | |
| ATR | $0.59 | |
| 14-Day RSI | 43.14 | |
| 10-Day Volatility | 24.32% | |
| 1-Year Volatility | 54.39% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $18.76M | |
| EPS | -$4.97 | |
| Gross Profit | $14.60M | |
| Gross Margin | 77.87% | |
| Operating Profit | -$745.94M | |
| Operating Margin | -3,977.30% | |
| Net Income | -$684.63M | |
| Net Margin | -3,650.39% | |
| EBITDA | -$741.79M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.03 | |
| 9.20 | ||
| 9.20 | ||
| - | ||
| 1 | ||
| 3.20 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 110.06 | ||
| 1.22 | ||
| -0.56 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $1.69B | |
| $1.70B | ||
| $1.96B | ||
| $1.80B | ||
| $269.45M | ||
| $195.45M | ||
| Total Debt | $49.25M | |
| $3.94M | ||
| $12.40M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $703.39M | ||
| $760.55M | ||
| $4.15M | ||
| $0.00 | ||
| $4.15M | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$650.44M | ||
| -$38.04M | ||
| $850.99M | ||
| Capex | $13.32M | |
| -$663.76M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | ||
| Chardan Capital | → | |
| TD Cowen | → | |
| RBC Capital | → | |
| Chardan Capital | → | |
| Raymond James | → | |
| Needham | → | |
| Leerink Partners | → | |
| HC Wainwright & Co. | → | |
| Citigroup | → |
Analyst sentiment
Institutional ownership
Screeners with RNA
FAQ
What is the ticker symbol for Atrium Therapeutics, Inc.?
The ticker symbol for Atrium Therapeutics, Inc. is NASDAQ:RNA
Does Atrium Therapeutics, Inc. pay dividends?
No, Atrium Therapeutics, Inc. does not pay dividends
What sector is Atrium Therapeutics, Inc. in?
Atrium Therapeutics, Inc. is in the Healthcare sector
What industry is Atrium Therapeutics, Inc. in?
Atrium Therapeutics, Inc. is in the Biotechnology industry
What country is Atrium Therapeutics, Inc. based in?
Atrium Therapeutics, Inc. is headquartered in United States
When did Atrium Therapeutics, Inc. go public?
Atrium Therapeutics, Inc. initial public offering (IPO) was on February 27, 2026
Is Atrium Therapeutics, Inc. in the S&P 500?
No, Atrium Therapeutics, Inc. is not included in the S&P 500 index
Is Atrium Therapeutics, Inc. in the NASDAQ 100?
No, Atrium Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Atrium Therapeutics, Inc. in the Dow Jones?
No, Atrium Therapeutics, Inc. is not included in the Dow Jones index
When was Atrium Therapeutics, Inc. last earnings report?
Atrium Therapeutics, Inc.'s most recent earnings report was on March 2, 2026
When does Atrium Therapeutics, Inc. report earnings?
The next expected earnings date for Atrium Therapeutics, Inc. is May 11, 2026
Data Sources & References
- RNA Official Website www.atriumtherapeutics.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1599901/000159990126000031/0001599901-26-000031-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1599901/000159990126000031/0001599901-26-000031-index.htm
- RNA Profile on Yahoo Finance finance.yahoo.com/quote/RNA
- RNA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rna